KoBioLabs, Inc.
Financials
Valuation Metrics
KoBioLabs, Inc.'s Market Cap is ₩518B. At end of 2025 it was ₩1113B. Ranked #1697 of 2,410 in KR market (top 70%), #1024 of 1,631 on KOSDAQ (top 63%), #184 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 80%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 51.85B KRW | KR#1,697/2,410 Sec#184/231 |
| Revenue | 75.41B KRW | KR#1,576/2,410 Sec#101/231 |
| Net Income | -4.79B KRW | KR—/2,410 Sec—/231 |
| Total Assets | 92.03B KRW | KR#1,844/2,410 Sec#147/231 |
| Net Assets | 45.42B KRW | KR#1,965/2,410 Sec#168/231 |
| Employees | 57 | KR#1,981/2,410 Sec#177/231 |
| Value | ||
| P/B | 1.14x | KR#1,637/2,410 Sec#106/231 |
| P/S | 0.69x | KR#1,180/2,410 Sec#58/231 |
| FCF Yield | -11.73% | KR—/2,410 Sec—/231 |
| Profitability | ||
| ROE | -10.54% | KR#1,951/2,410 Sec#147/231 |
| ROA | -5.20% | KR#1,936/2,410 Sec#139/231 |
| Op. Margin | -10.70% | KR#1,994/2,410 Sec#135/231 |
| Revenue Growth | 8.58% | KR#969/2,410 Sec#96/231 |
| Financial Health | ||
| Debt Ratio | 102.63% | KR#1,576/2,410 Sec#181/231 |
| Total Debt | 16.47B KRW | KR#1,451/2,410 Sec#120/231 |
| FCF | -6.08B KRW | KR#1,548/2,410 Sec#124/231 |
| Cash | 14.63B KRW | KR#1,449/2,410 Sec#117/231 |
| Current Ratio | 3.38x | KR#481/2,410 Sec#71/231 |
| Performance | ||
| 1Y Return | -46.92% | KR#1,888/2,410 Sec#166/231 |
| 1M Return | -10.70% | KR#1,096/2,410 Sec#107/231 |
| From 52W High | -69.42% | KR#2,044/2,410 Sec#170/231 |
| 1Y MDD | -61.24% | KR#1,517/2,410 Sec#121/231 |
| Trading | ||
| Volume | 5,349 shares | KR#1,979/2,410 Sec#200/231 |
| Trading Value | 14.4M KRW | KR#2,064/2,410 Sec#217/231 |
| Foreign Own. | 2.80% | KR#1,351/2,410 Sec#126/231 |
| Per Share | ||
| EPS | -246 KRW | KR—/2,410 Sec—/231 |
| BPS | 2,339 KRW | KR#2,004/2,410 Sec#163/231 |
Company Info
KoBioLabs, established in 2014 and listed on KOSDAQ in 2020, is a microbiome-specialized biotech company. It develops human microbiome-based therapeutics like CUREbiotics and operates a health functional food business, producing and selling probiotic products via its subsidiary, WeBiome. Through its Smartiome 2.0 new drug development platform, the company has established a therapeutic pipeline for immune diseases and secured core competitiveness in the bio sector by commencing global clinical trials for microbiome new drugs.